Diabetic-Check-up

Diabetic-Check-up - DiaPat®-DC test

Diabetics (type 1 and type 2) are especially affected by chronic loss of renal function (diabetic nephropathy) and by coronary artery disease (CAD). Patients with a diabetic metabolic status have an increased risk for cardiovascular diseases.

Analysing the urine sample, DiaPat®-DC test is a non-invasive, riskless and reliable method that allows early diagnosis of diabetic nephropathy and coronary artery disease. Suitable therapy at this early stage can not only prevent or substantially delay onset of diabetic nephropathy, but also reduce the high infarction risk of diabetes patients.

 

 

Advantages of the DiaPat®-DC test

• Painless (non-invasive urine sample)
• Riskless (sampling)
• Reliable (detection of both diabetic nephropathy and coronary artery disease with high accuracy)

 

Comparison of current methods

Conventional cardiovascular diagnostics	Conventional renal diagnostics	One test - two areas of expertise
ECG Echocardiography PET scanning Magnetic resonance tomography Cardiac computer tomography Coronary angiography	Renal function test Proteinuria test Sonography	DiaPat - DC

Due to the interaction of heart and kidneys, diseases of the renal and of the cardiovascular system create a vicious circle, leading to steadily worsening pathological changes in both systems (cardio-renal syndrome).

 

Diabetic Nephropathy - DiaPat®-DN test

The DiaPat®-DN test allows the detection of diabetic nephropathy.

 

Figure: Adoption of the DiaPat-DN test (diabetic nephropathy) (Zoom in)

 

Prevalence:

In recent years, particularly the number of patients with renal insufficiency as well as type II diabetes mellitus and consequently the number of type II diabetics requiring dialysis has risen significantly in the industrialised countries. According to latest estimates, patients with type II diabetes constitute 35% of the total dialysis population in Germany. These figures show that nephropathy in type II diabetes - as well as underlying diseases - has reached epidemic dimensions. It is anticipated that worldwide the number of patients affected by diabetes will double from 180 million today to almost 370 million by the year 2030. Observational studies show a three- to tenfold increased risk for cardiovascular morbidity and mortality in type I diabetes mellitus; in type II diabetics the risk is increased two-to fourfold. Therefore, in the field of diabetes mellitus early diagnosis and prevention of both diabetic nephropathy and cardiovascular disease is of particular importance.

References:

Mischak H, Kaiser T, Walden M et al.
Proteomic analysis for the assessment of diabetic renal damage in humans.
Clin Sci (Lond) 2004; 107: 485-495

Meier M, Kaiser T, Herrmann A et al.
Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis.
J Diabetes Complications 2005; 19: 223-232

Rossing K, Mischak H, Rossing P, Schanstra JP, Wiseman A, Maahs DM.
The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy.
Proteomics Clin Appl 2008; 2: 997-1007

Rossing K, Mischak H, Dakna M et al.
Urinary Proteomics in Diabetes and CKD.
J Am Soc Nephrol 2008; 19: 1283-1290

Snell-Bergeon JK, Maahs DM, Ogden LG et al.
Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease.
Diabetes Technol Ther 2009; 11: 1-9